Tetraspanin CD151 is a novel prognostic marker in poor outcome endometrial cancer

BACKGROUND: Type II cancers account for 10% of endometrial cancers but 50% of recurrence. Response rates to chemotherapy at recurrence are poor and better prognostic markers are needed to guide therapy. CD151 is a small transmembrane protein that regulates cell migration and facilitates cancer metas...

Descripción completa

Detalles Bibliográficos
Autores principales: Voss, M A, Gordon, N, Maloney, S, Ganesan, R, Ludeman, L, McCarthy, K, Gornall, R, Schaller, G, Wei, W, Berditchevski, F, Sundar, S
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3101917/
https://www.ncbi.nlm.nih.gov/pubmed/21505452
http://dx.doi.org/10.1038/bjc.2011.80

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3101917/
https://www.ncbi.nlm.nih.gov/pubmed/21505452
http://dx.doi.org/10.1038/bjc.2011.80

Ejemplares similares